Similar results have recently been seen in T790M-positive NSCLC patients receiving osimertinib as second- or third-line, in that those with co-existing EGFR exon 19del displayed longer PFS and OS than patients harboring L858R co-mutation [23]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.